Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vernalis

Vernalis?uq=UG6efJS6
1986 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
VER.GB STOCK SYMBOL
3 INVESTMENTS
$0.08 SHARE PRICE (As of Thursday Closing)
Description

Developer of bio-medical products created for the treatment of several diseases. The company's products include prescribed and non-prescribed drugs used for the treatment of migraine, cough, cold and tonsillitis, enabling pharmaceutical and medical companies to get a wide range of over the counter medicines.

Formerly Known As
British Biotech, Vanguard Medica
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Other Commercial Services
Stock Exchange
NEXX
Primary Office
  • 100 Berkshire Place
  • Wharfedale Road
  • Winnersh RG41 5RD
  • England

+44 0118 000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Vernalis’s full profile, request a free trial.

Vernalis Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.07 - $0.11 $43.4M $0.08 -$0.12 145K 527M

Vernalis Financials Summary

In Thousands,
USD
TTM
31-Dec-2017
FY 2017
30-Jun-2017
FY 2016
30-Jun-2016
FY 2015
30-Jun-2015
Enterprise Value (17,890) 30,047 157,052
Revenue 28,625 26,365 17,749 31,281
EBITDA (61,811) (28,936) (21,047) (12,952)
Net Income (61,919) (27,344) (21,378) (10,071)
Total Assets 74,919 122,514 150,151 136,139
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vernalis Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Vernalis‘s full profile, request access.

Request full access to PitchBook

Vernalis Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 0000000000000 18-Nov-2005 000000000000000000 0000 Biotechnology
000000 00000000000 01-Apr-2005 000000000000000000 Diagnostic Equipment
Cerebrus Pharmaceuticals 03-Dec-1999 Merger/Acquisition 000.00 Drug Discovery
To view this company’s complete investment and acquisition history, request access »

Vernalis Executive Team (4)

Name Title Board
Seat
Contact
Info
Ian Garland Chief Executive Officer and Board Member
David Mackney Chief Financial Officer and Board Member
Sandford Sommer President and Chief Operating Officer
Peter Fellner Ph.D Chairman

Vernalis Board Members (7)

Name Representing Role Since Contact
Info
00000 00000000 Vernalis Board Member 000 0000
00000 0000000 Vernalis Chief Financial Officer and Board Member 000 0000
000 0000000 Vernalis Chief Executive Officer and Board Member 000 0000
000 000000 00.0 Vernalis Board Member 000 0000
0000 0000000000 Vernalis Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »